Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: J Mol Cell Cardiol. 2015 Jan 14;81:54–61. doi: 10.1016/j.yjmcc.2015.01.003

Figure 3.

Figure 3

Negative shift in the nitroso-redox balance decreased phospholamban (PLB) phosphorylation via phosphatase activation. Summary data of PLB Serine16 phosphorylation (A) and phosphatase activity (B) in Sed and Ex-nNOSKO myocytes (±O2·− scavenger MENO) (n=4 hearts/group), * P<0.05 vs corresponding Sed. C) Summary data of phosphatase activity in Sed and Ex WT myocytes (±nNOS inhibitor SMLT) (n=4 hearts/group), # P<0.05 vs Sed-WT, * P<0.05 vs corresponding control. D) Summary data of PLB Serine16 phosphorylation in control (non-induced) and nNOSOE myocytes (n=6 hearts/group), * P<0.05.